Cargando…
1925. Prevalence of SARS-CoV-2 Infection in Immunocompromised Patients Following Receipt of Tixagevimab/Cilgavimab
BACKGROUND: Tixagevimab/cilgavimab (TC) was approved by the FDA in December 2021 for use as pre-exposure prophylaxis in patients with moderate to severe immune compromise. On February 24, FDA recommended a second dose for patients who received the original dosing because of decreased activity agains...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752616/ http://dx.doi.org/10.1093/ofid/ofac492.1552 |